sivelestat has been researched along with 2019 Novel Coronavirus Disease in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 6 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jenne, DE; Korkmaz, B; Lesner, A; Marchand-Adam, S; Moss, C | 1 |
| Chen, Y; Cui, Y; Deng, Y; Fu, Q; Jiang, P; Li, J; Lin, J; Liu, Y; Meng, Q; Sun, Y; Wang, L; Wang, M; Xu, H; Ye, B; Zhang, M; Zhang, S; Zhang, T; Zhao, X | 1 |
| Hu, H; Liu, Y; Luo, M; Sun, Y; Wu, G; Zeng, Z; Zhao, X | 1 |
| Becker, C; Benoliel, JJ; Elbim, C; Frère, C; Hémadi, M; Laforge, M; Massaad, C; Nuss, P | 1 |
| Avan, R; Bagheri, M; Habtemariam, S; Khataminia, M; Rezai Ghaleno, H; Sadremomtaz, A; Safdari, M; Saghafi, F; Sahebnasagh, A; Talaei, Z | 1 |
| Al-Rejaie, S; ElMasry, G; Kishk, RM; Kishk, SM; Nafie, MS; Nemr, NA; Simons, C; Yassen, ASA | 1 |
2 review(s) available for sivelestat and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Lung Protection by Cathepsin C Inhibition: A New Hope for COVID-19 and ARDS?
Topics: Animals; Cathepsin C; Cell Line, Tumor; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Humans; Lung; Neutrophil Infiltration; Neutrophils; Protease Inhibitors; Respiratory Distress Syndrome | 2020 |
Neutrophil elastase inhibitor (sivelestat) may be a promising therapeutic option for management of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19.
Topics: Acute Lung Injury; COVID-19; COVID-19 Drug Treatment; Disseminated Intravascular Coagulation; Glycine; Humans; Proteinase Inhibitory Proteins, Secretory; Respiratory Distress Syndrome; Sulfonamides; Treatment Outcome | 2020 |
4 other study(ies) available for sivelestat and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Elastase Inhibitor Cyclotheonellazole A: Total Synthesis and In Vivo Biological Evaluation for Acute Lung Injury.
Topics: Acute Lung Injury; Animals; Bleomycin; Cell Line; COVID-19; COVID-19 Drug Treatment; Disease Models, Animal; Humans; Leukocyte Elastase; Male; Mice; Mice, Inbred C57BL; Peptides, Cyclic; Respiratory Distress Syndrome; Serine Proteinase Inhibitors | 2022 |
[Sivelestat sodium for treatment of patients with COVID-19-associated acute respiratory distress syndrome in intensive care unit: a single-center retrospective cohort study].
Topics: C-Reactive Protein; COVID-19; Critical Illness; Humans; Intensive Care Units; Interleukin-6; Pneumonia; Procalcitonin; Retrospective Studies | 2023 |
Tissue damage from neutrophil-induced oxidative stress in COVID-19.
Topics: Acetylcysteine; Antioxidants; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokines; Drug Therapy, Combination; Extracellular Traps; Gene Expression Regulation; Glycine; Host-Pathogen Interactions; Humans; Immunity, Innate; Lung; Lymphocytes; Neutrophils; NF-E2-Related Factor 2; NF-kappa B; Oxidative Stress; Pandemics; Pneumonia, Viral; Proteinase Inhibitory Proteins, Secretory; Reactive Oxygen Species; SARS-CoV-2; Severity of Illness Index; Sulfonamides; Superoxide Dismutase | 2020 |
Molecular Insights into Human Transmembrane Protease Serine-2 (TMPS2) Inhibitors against SARS-CoV2: Homology Modelling, Molecular Dynamics, and Docking Studies.
Topics: Antiviral Agents; Benzamidines; Betacoronavirus; Coronavirus Infections; COVID-19; Esters; Gabexate; Glycine; Guanidines; Humans; Ligands; Models, Molecular; Molecular Docking Simulation; Molecular Dynamics Simulation; Pandemics; Pneumonia, Viral; Protein Structure, Tertiary; SARS-CoV-2; Sequence Homology, Amino Acid; Serine Endopeptidases; Serine Proteinase Inhibitors; Sulfonamides | 2020 |